

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Zylox-Tonbridge Medical Technology Co., Ltd.

歸創通橋醫療科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2190)

POLL RESULTS OF EXTRAORDINARY GENERAL MEETING HELD ON OCTOBER 19, 2023

Reference is made to the announcement of Zylox-Tonbridge Medical Technology Co., Ltd. (the “**Company**”) dated September 27, 2023 (the “**Announcement**”) and the circular of the Company dated October 3, 2023 (the “**Circular**”). Unless the context otherwise requires, capitalized terms used in this announcement shall have the same meanings as those defined in the Announcement and the Circular.

The Board wishes to announce that the EGM was convened and held at Meeting Room 202, 2nd Floor, Zylox-Tonbridge Industrial Park, No. 270 Shuyun Road, Cangqian Street, Yuhang District, Hangzhou, Zhejiang, the PRC on Thursday, October 19, 2023, and the special resolution proposed at the EGM was duly passed.

As at the date of the EGM, the total number of Shares in issue was 332,401,001 (including 7,781,257 Domestic Shares and 324,619,744 H Shares). The number of Shareholders and proxies of Shareholders attending the EGM was 1. Shareholders and proxies of Shareholders who attended the EGM held a total of 243,032,984 Shares with voting rights (including 7,781,257 Domestic Shares and 235,251,727 H Shares), representing approximately 73.11% of the total number of Shares with voting rights.

To the best knowledge, information and belief of the Directors: (1) no Shareholders were required under the Listing Rules to abstain from voting on the resolution; (2) there were no Shares entitling the holders thereof to attend the EGM and abstain from voting in favor of the resolution under Rule 13.40 of the Listing Rules; and (3) no Shareholders have indicated in the Circular that they intend to vote against or to abstain from voting on the resolution.

Tricor Investor Services Limited, the Company's H share registrar, acted as the scrutineer for the vote-taking at the EGM. The convening of the EGM was in compliance with the Company Law of the PRC and the Articles of Association.

Dr. Jonathon Zhong Zhao, an executive Director attended the Meetings in person; while Mr. Yang Xie and Dr. Zheng Li, both being executive Directors; Mr. Stephen Hui Wang, Dr. Steven Dasong Wang and Mr. Dongfang Li, all being non-executive Directors; and Dr. Jian Ji, Mr. Hongze Liang and Ms. Yun Qiu, all being independent non-executive Directors, attended the Meetings by electronics means.

The poll results in respect of the resolution proposed at the EGM were as follows:

Special Resolution		Number of votes (%)	
		For	Against
1.	To consider and approve the Proposed Amendments to the Articles of Association.	229,556,367 (94.45%)	13,476,617 (5.55%)

As more than two-thirds of the votes from the Shareholders (including their proxies) attending the EGM were cast in favor of the special resolution, the resolutions was duly passed as a special resolution of the Company.

AMENDMENTS TO THE ARTICLES OF ASSOCIATION

The Board hereby announces that the resolution to approve the Proposed Amendments has been duly passed as a special resolution of the Company at the EGM. For details of the Proposed Amendments, please refer to the Appendix to the Circular. The full text of the revised Articles of Association will be available on the websites of the Stock Exchange (www.hkexnews.hk) and the Company (www.zyloxtb.com), respectively.

By order of the Board
Zylox-Tonbridge Medical Technology Co., Ltd.
Dr. Jonathon Zhong Zhao
Chairman and Executive Director

Hong Kong, October 19, 2023

As of the date of this announcement, the Board comprises Dr. Jonathon Zhong Zhao, Mr. Yang Xie and Dr. Zheng Li as executive Directors, Mr. Stephen Hui Wang, Dr. Steven Dasong Wang and Mr. Dongfang Li as non-executive Directors, and Dr. Jian Ji, Mr. Hongze Liang and Ms. Yun Qiu as independent non-executive Directors.